JPH0376294B2 - - Google Patents
Info
- Publication number
- JPH0376294B2 JPH0376294B2 JP58089290A JP8929083A JPH0376294B2 JP H0376294 B2 JPH0376294 B2 JP H0376294B2 JP 58089290 A JP58089290 A JP 58089290A JP 8929083 A JP8929083 A JP 8929083A JP H0376294 B2 JPH0376294 B2 JP H0376294B2
- Authority
- JP
- Japan
- Prior art keywords
- cachexia
- pronase
- treatment
- drugs
- cell count
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010006895 Cachexia Diseases 0.000 claims description 16
- 108010059712 Pronase Proteins 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004820 blood count Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58089290A JPS59225122A (ja) | 1983-05-23 | 1983-05-23 | 悪液質治療改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58089290A JPS59225122A (ja) | 1983-05-23 | 1983-05-23 | 悪液質治療改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59225122A JPS59225122A (ja) | 1984-12-18 |
| JPH0376294B2 true JPH0376294B2 (en]) | 1991-12-05 |
Family
ID=13966559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58089290A Granted JPS59225122A (ja) | 1983-05-23 | 1983-05-23 | 悪液質治療改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59225122A (en]) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0676339B2 (ja) * | 1985-09-13 | 1994-09-28 | 浩 前田 | 制癌剤 |
| JPH02292226A (ja) * | 1989-05-08 | 1990-12-03 | Shigemi Fujisaki | 障害された神経細胞賦活予防治療剤 |
| GB9412711D0 (en) * | 1994-06-24 | 1994-08-17 | Cortecs Ltd | Medical use of bromelain |
| US20020102253A1 (en) | 1997-02-25 | 2002-08-01 | Mynott Tracey Lehanne | Component of bromelain |
-
1983
- 1983-05-23 JP JP58089290A patent/JPS59225122A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59225122A (ja) | 1984-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sherman et al. | Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis | |
| Rutgeerts et al. | A comparison of budesonide with prednisolone for active Crohn's disease | |
| Rammohan et al. | Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients | |
| Jewell | Corticosteroids for the management of ulcerative colitis and Crohn’s disease | |
| Cohen et al. | Fatal hepatic necrosis secondary to isoniazid therapy | |
| CN107308141B (zh) | 石斛酚在制备预防和治疗动脉粥样硬化药物中的应用 | |
| JPH0376294B2 (en]) | ||
| WO2006043153A2 (en) | Use of zinc and copper chelators for the treatment of viral diseases | |
| Stavinoha et al. | Current therapy of chronic liver disease | |
| EP4547249A1 (en) | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis | |
| CN103055164B (zh) | 一种治疗单纯舒张期高血压的中药组合物 | |
| SE514128C2 (sv) | Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit | |
| Sho et al. | Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C | |
| JPH0213647B2 (en]) | ||
| Sakarcan et al. | Antibiotic-induced recurring interstitial nephritis | |
| Sousa et al. | Pyoderma gangrenosum leading to bilateral involvement of ears | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| WO2003022292A1 (fr) | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation | |
| Ikenouchi et al. | Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody | |
| JPS5938204B2 (ja) | 再生不良性貧血治療剤 | |
| Wai et al. | METASTATIC MEDULLARY THYROID CARCINOMA DESPITE PROPHYLACTIC TOTAL THYROIDECTOMY IN MULTIPLE ENDOCRINE NEOPLASIA (MEN) 2A | |
| CN114949200A (zh) | 全反式维a酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发itp的药物中的应用 | |
| NO134185B (en]) | ||
| WO2009084732A1 (ja) | インターフェロン・リバビリン併用療法における副作用軽減剤 | |
| Izha | Тhe role of the internal use of mineral water in the complex treatment of patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease |